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Abstract
Background: People living with HIV (PLHIV) who are also marginalized by social and structural inequities often face
barriers to accessing and adhering to HIV treatment and care. The Dr. Peter Centre (DPC) is a non-profit integrated
care facility with a supervised injection room that serves PLHIV experiencing multiple barriers to social and health
services in Vancouver, Canada. This study examines whether the DPC is successful in drawing in PLHIV with
complex health issues, including addiction.
Methods: Using data collected by the Longitudinal Investigations into Supportive and Ancillary health services
(LISA) study from July 2007 to January 2010, linked with clinical variables available through the British Columbia
Centre for Excellence in HIV/AIDS Drug Treatment Program, we identified DPC and non-DPC clients with a history
of injection drug use. Bivariable and multivariable logistic regression analyses compared socio-demographic and
clinical characteristics of DPC clients (n = 76) and non-DPC clients (n = 482) with a history of injection drug use.
Results: Of the 917 LISA participants included within this analysis, 100 (10.9%) reported being a DPC client, of
which 76 reported a history of injection drug use. Adjusted results found that compared to non-DPC clients with a
history of injection drug use, DPC-clients were more likely to be male (AOR: 4.18, 95% CI = 2.09–8.37); use
supportive services daily vs. less than daily (AOR: 3.16, 95% CI = 1.79–5.61); to have been diagnosed with a mental
health disorder (AOR: 2.11; 95% CI: 1.12–3.99); to have a history of interpersonal violence (AOR: 2.76; 95% CI: 1.23–6.
19); and to have ever experienced ART interruption longer than 1 year (AOR: 2.39; 95% CI: 1.38–4.15).
Conclusions: Our analyses suggest that the DPC operating care model engages PLHIV with complex care needs,
highlighting that integrated care facilities are needed to support the multiple intersecting vulnerabilities faced by
PLHIV with a history of injection drug use living within urban centres in North America and beyond.
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Background
Globally, there are an estimated 3 million people living
with HIV (PLHIV) who inject drugs [1, 2]. Within these
populations, issues such as delayed HIV testing, low up-
take of antiretroviral therapy (ART), ART treatment in-
terruptions, and the need for management of HIV and
HIV-related opportunistic infections are pertinent issues
[3]. HIV infection has been shown to increase the risk of
overdose-related mortality in people who inject drugs
(PWID) [4]. The emergence of supervised injection facilities
(SIFs)—locations in which PWID consume pre-obtained
illicit drugs under staff supervision—aims to address these
health-related challenges by providing sterile syringes to
PWID, referrals to primary health services, and emergency
care in the event of an overdose [5]. In Vancouver, B.C, the
Dr. Peter Centre (DPC) operates under a comprehensive
harm reduction approach that includes the availability of
nurse-supervised injection services in a room located inside
the facility, and the provision of harm reduction sup-
plies (e.g., sterile syringes, alcohol swabs). Serving as a
multidisciplinary integrated HIV care facility, the DPC
was established to address health disparities faced by
underserved PLHIV by providing care and support ser-
vices (see DPC services in Table 1). All DPC clients
must undergo a referral and admission process before
accessing DPC services. Eligibility for DPC admission in-
cludes HIV positive diagnosis, deteriorating health, and
demonstrated need for support in order to maintain inde-
pendence in the community. While there are demonstrated
benefits of a specialized integrated approach to care for
PLHIV who inject drugs based on need [6], previous
research has not focused specifically on the integration
of harm reduction, including SIFs, into these health
care environments.
This study sought to characterize the engagement of
PLHIV who use(d) illicit drugs and access the DPC.
Specifically, this analysis aimed to understand how an
integrated model of care that includes a harm reduc-
tion approach could be effective amongst PLHIV margin-
alized by socio-structural inequities (e.g., homelessness,
drug criminalization) both in Vancouver, as well as in
other settings.
Methods
Recruitment
The Drug Treatment Program at the BC Centre for Ex-
cellence in HIV/AIDS is mandated by the provincial
government to distribute ART free of charge to all eli-
gible PLHIV. Individuals are entered into the Drug
Treatment Program when they are first prescribed ART,
and a complete prospective profile of ART is maintained
[7]. Individuals enrolled in the Drug Treatment Program
who were over the age of 19, residents of BC, and able
to provide informed consent were eligible to participate
in the Longitudinal Investigations into Supportive and
Ancillary health services (LISA) study, the aim of which
was to examine the experiences of harder-to-reach PLHIV
who have accessed ART in BC. The LISA cohort has been
previously described in detail [8].
Outcome and explanatory variables
Our primary outcome variable was self-reported use of
DPC services, ascertained by two questions in the LISA
survey: (1) what type of place do you live in right now? (Dr.
Peter Centre residence provided as an option), and (2) what
three agencies or organizations do you use most regularly?
Table 1 Dr. Peter Centre Services
Art, music, and recreation, complimentary therapy
Weekly activities offered including gardening, fitness, yoga, and acupuncture.
Therapies allow for opportunities to stimulate self-awareness, self-expression,
communication, personal development, and greater self-care
● Individual art therapy
● Open art therapy
● Group music therapy
● Music jam
● Karaoke
● Performances
● Recreational therapy
● Special events
● Community garden
● Exercise program/room
● Group leisure activities
(Bingo, games, activities
in the living room)
● Pet visits by volunteers
● Complementary therapies
(yoga, Reiki, acupuncture)
Support and counseling
Counseling services offered to help build emotional strength and
support mental health and wellness. Supports for problems
surrounding addiction and substance use issues
● Men’s group
● Women’s evening group
● Indigenous group
● Individual counseling
● Group counseling
● Assistance with housing
● Community service resources
● Scheduling appointments and
transportation
Nursing and dietetics
Nurses provide health assessments, medication assistance, and
consultation for symptom management. They also play a key role in
helping participants successfully engage in HAART treatment. ART
adherence support helps to suppress the HIV virus, as well as prevent
new HIV transmissions
● Medication support
● Wound care health
teaching
● Supervised injection services
● Harm reduction supplies
● Foot clinic
Amenities:
DPC clients have access to a variety of amenities
● Nap room
● Newspapers
● Showers
● Laundry
● Telephones
● Computers
● Library
● TV room
● Movies
Food and nutrition
Wholesome nutrient-dense meals and dietary guidance for
improved health. Meals are offered twice a day, 7 days a week
● Breakfast
● Lunch
● Snacks
● Coffee
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(space provided for participant to name specific agency).
Table 2 shows the self-reported socio-demographic and
psychosocial variables that were included in this analysis:
gender (male vs. female vs. transgender), Indigenous ances-
try, housing status (stable [house, apartment] vs. un-
stable [room in hotel, shelter/hostel, no fixed address,
recovery house, the DPC, jail]), relationship status (in a re-
lationship [married, common-law, regular partner, non-
regular partner] vs. [single, divorced, separated, widowed]),
employment status, use of supportive services (daily vs.
<daily), self-reported physician-diagnosed mental health
disorder, self perceived health now compared to a year prior
to the interview (better vs. worse vs. same), having experi-
enced interpersonal violence (ever vs. never), and history of
incarceration (ever vs. never). Table 2 also shows clinical
variables retrieved from the Drug Treatment Program
included in this analysis: ART interruption lasting lon-
ger than 1 year between the first ART date and the time
of interview, CD4 cell count at the time of interview, and
prescription dispensation period (number of days between
the two closest dispense dates before interview date).
Inclusion criteria and statistical analysis
In order to be included in this analysis, participants were
required to report a history of ever injecting drugs. A de-
scriptive profile of PWID within the LISA study comparing
those who are clients of the DPC vs. those who are not
DPC clients was established by conducting the Chi-square
test for categorical variables, and the Wilcoxon rank-sum
test for continuous variables. Explanatory variables of inter-
est were selected using Akaike information criterion
minimization.
Results
Between July 2007 and January 2010, interviews were con-
ducted with over 1000 participants, of whom 917 had
complete clinical data within the Drug Treatment Program.
Among 917 LISA participants, 100 (10.9%) were DPC
Table 2 Bivariable and multivariable comparisons of PWID who are clients of DPC vs. non-clients (n = 558)
Variable Non-DPC clients
n = 482
n (%)
DPC Clients
n = 76
n (%)
P value Unadjusted odds ratio
(95% confidence interval)
Adjusted odds ratio
(95% confidence interval)
Socio-demographic and psychosocial indicators
Gender Female
Male
Transgender
176 (36.51)
300 (62.24)
6 (1.24)
11 (14.47)
64 (84.21)
1 (1.32)
<0.001 1.00
3.24 (1.70–6.16)
1.00
4.18 (2.09–8.37)
Indigenous ancestry Yes
No
163 (33.82)
319 (66.18)
24 (31.58)
52 (68.42)
0.701 – –
Housing status Stable
Unstable
249 (51.66)
233 (48.34)
38 (50)
38 (50)
0.788 1.00
0.94 (0.58–1.52)
–
Relationship status In a relationship
Single
160 (33.20)
321 (66.60)
13(17.11)
63(82.89)
0.008 – –
Employment status Yes
No
66 (13.69)
416 (86.31)
4 (5.26)
72 (94.74)
0.039 – –
Supportive service use <daily
Daily
216 (48.55)
229 (51.46)
17 (23.29)
56 (76.71)
<0.001 1.00
3.09 (1.80–5.31)
1.00
3.16 (1.79–5.61)
Mental health disorder diagnosis No
Yes
153 (31.74)
329 (68.26)
17 (22.37)
59 (77.63)
0.099 1.00
1.61 (0.91–2.86)
1.00
2.11 (1.12–3.99)
Health compared to 1 year ago Better
Worse
Same
232 (48.13)
148 (30.71)
102 (21.16)
32 (42.11)
18 (23.68)
26 (34.21)
0.040 – –
Interpersonal violence No
Yes
96 (19.96)
385 (80.04)
8 (10.67)
67 (89.33)
0.055 1.00
2.09 (0.97–4.49)
1.00
2.76 (1.23–6.19)
Incarceration Ever
Never
351 (72.82)
131 (27.18)
55 (72.37)
21 (27.63)
0.934 1.00
0.98 (0.57–1.68)
–
Clinical indicators
ART interruption for >1 year No
Yes
220 (45.64)
262 (54.36)
47 (61.84)
29 (38.16)
0.009 1.00
1.93 (1.18–3.17)
1.00
2.39 (1.38–4.15)
CD4 at time of interview Median
(IQR)
300
(190–460)
285
(150–470)
0.602 0.98
(0.88–1.09)
–
Prescription dispense period Median
(IQR)
52
(28–66)
38.5
(26.5–60.5)
0.058 0.93
(0.82–1.07)
–
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clients. Table 2 compares individuals with a history of injec-
tion drug use who are DPC clients (n = 76) to individuals
with a history of injection drug use who are not DPC cli-
ents (n = 482).
The results of the bivariable analysis suggest that DPC cli-
ents were less likely to be female (14.5 vs. 36.5%; p ≤ 0.001),
in a relationship (17.1 vs. 33.2%; p = 0.008), employed (5.26
vs. 13.7%; p = 0.04), and more likely to use supportive ser-
vices daily (76.7 vs. 51.5%, p ≤ 0.001) compared to non-DPC
clients. DPC clients were less likely to report their health to
be better than a year ago compared to non-DPC clients
(42.1 vs. 48.1%; p = 0.04). DPC clients were more likely to
have ever experienced ART interruption for more than
1 year between the first ART date and interview date (61.8
vs. 45.6%, p= 0.009).
Multivariable results found that compared to those who
were not DPC clients, DPC clients were more likely to be
male compared to female (adjusted odds ratio [AOR]: 4.18;
95% confidence interval [CI]: 2.09–8.37), to use supportive
services daily (AOR: 3.16; 95% CI: 1.79–5.61), have been di-
agnosed with a mental health disorder (AOR: 2.11; 95% CI:
1.12–3.99), have a history of interpersonal violence (AOR:
2.76; 95% CI: 1.23–6.19), and to have ever experienced
ART interruption longer than 1 year (AOR: 2.39; 95% CI:
1.38–4.15).
Discussion
In summary, PLHIV with a history of injection drug use
and who report attending the DPC experience more com-
plex health challenges in comparison to those who do not
report attending the DPC. A greater number of partici-
pants who are clients of the DPC compared to non-DPC
clients have experienced interpersonal violence, have ever
been diagnosed with a mental health disorder, and have
ever experienced HIV treatment interruption. The mutu-
ally reinforcing experiences of violence, trauma, and men-
tal health concerns among PLHIV have been documented
in the literature as a syndemic [9–11]. This is aligned with
our finding that DPC clients with a history of injection
drug use are more than twice as likely to have been
diagnosed with a mental health condition compared to
their non-DPC client counterparts. Untreated mental
health disorders can make navigating conventional health
care systems arduous, often leaving PLHIV who live with
these conditions more likely to experience suboptimal
treatment and health outcomes [12]. Syndemic health is-
sues, such as mental health and illicit drug use, interfere
with individuals managing their HIV, and engaging in safer
practices, thus acting as barriers to adequate care [12].
Therefore, specialized health care services targeting PLHIV
with complex health issues are necessary for optimization
of health outcomes.
Use of daily support services by DPC clients was ap-
proximately three times higher when compared to their
non-DPC client counterparts. These findings suggest
that integrated healthcare approaches are necessary to sup-
port PLHIV with complex health issues, including injection
drug use. The DPC provides a range of services appealing
to the diverse healthcare needs of clients. Engagement with
the facility occurs through multiple entry points (e.g., meal
program, medication support) that may ultimately lead
to different trajectories of service use to promote over-
all health, and may improve client retention.
There are several limitations to consider in this
study. Results should be interpreted with caution, as
the measurement of lifetime history of injection drug
use does not necessarily correspond to current drug
use. In addition, potential information bias is import-
ant to note as socio-demographic and psychosocial
indicators were self-reported in the LISA survey.
Conclusions
In conclusion, DPC clients with a history of injection drug
use experience more complex health issues than PWID
who are not DPC clients. However, our analyses demon-
strate that the DPC integrated model of care helps facili-
tate access to support services for this population. The
DPC’s referral and selection criteria successfully capture
and engage key populations experiencing complex health
issues. Further research on integrated health care facilities,
including harm reduction services, should be conducted
to examine whether they improve treatment outcomes
and quality of life among key populations living with HIV.
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